Long-term outcomes of sensitized lung transplant recipients
The Toronto Lung Transplant Program has been using a peri-operative desensitization regimen of plasma exchange, intravenous immune globulin, and anti-thymocyte globulin in order to accept donor-specific antibody (DSA)-positive lung transplants safely.

Researchers extended their prior study to include long-term follow-up of 340 patients who received lung transplants. They compared allograft survival and chronic lung allograft dysfunction (CLAD)-free survival among patients in 3 cohorts: DSA-positive, panel reactive antibody (PRA)-positive/DSA-negative, and unsensitized at the time of transplant.

The median follow-up time in this extension study was 6.7 years. Among DSA-positive, PRA-positive/DSA-negative, and unsensitized patients, the median allograft survival was 8.4, 7.9, and 5.8 years, respectively, and the median CLAD-free survival was 6.8, 7.3, and 5.7 years, respectively.

This follow-up study confirms that long-term allograft survival and CLAD-free survival of patients who undergo DSA-positive lung transplants with the use of our protocol do not differ from other lung transplant recipients. The use of protocols, therefore, may improve access to transplants for sensitized candidates.

American Journal of Transplantation
Source: https://doi.org/10.1111/ajt.16707